DK1185525T3 - 4-heterocyclylsulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidinderivater, fremstilling deraf samt anvendelse deraf som endothelinreceptorantagonister - Google Patents

4-heterocyclylsulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidinderivater, fremstilling deraf samt anvendelse deraf som endothelinreceptorantagonister

Info

Publication number
DK1185525T3
DK1185525T3 DK00909263T DK00909263T DK1185525T3 DK 1185525 T3 DK1185525 T3 DK 1185525T3 DK 00909263 T DK00909263 T DK 00909263T DK 00909263 T DK00909263 T DK 00909263T DK 1185525 T3 DK1185525 T3 DK 1185525T3
Authority
DK
Denmark
Prior art keywords
methoxy
heterocyclylsulfonamidyl
phenoxy
pyridyl
preparation
Prior art date
Application number
DK00909263T
Other languages
English (en)
Inventor
Philippe Coassolo
Werner Neidhart
Sebastien Roux
Peter Weiss
Volker Breu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1185525T3 publication Critical patent/DK1185525T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
DK00909263T 1999-03-03 2000-02-28 4-heterocyclylsulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidinderivater, fremstilling deraf samt anvendelse deraf som endothelinreceptorantagonister DK1185525T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99104306 1999-03-03
PCT/EP2000/001660 WO2000052007A1 (en) 1999-03-03 2000-02-28 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists

Publications (1)

Publication Number Publication Date
DK1185525T3 true DK1185525T3 (da) 2007-06-04

Family

ID=8237697

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00909263T DK1185525T3 (da) 1999-03-03 2000-02-28 4-heterocyclylsulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidinderivater, fremstilling deraf samt anvendelse deraf som endothelinreceptorantagonister

Country Status (30)

Country Link
US (2) US6417360B1 (da)
EP (1) EP1185525B1 (da)
JP (1) JP3488203B2 (da)
KR (1) KR100478798B1 (da)
CN (1) CN1342158B (da)
AR (1) AR044720A1 (da)
AT (1) ATE353325T1 (da)
AU (1) AU756738B2 (da)
BR (1) BR0008717A (da)
CA (1) CA2364906C (da)
CY (1) CY1108002T1 (da)
CZ (1) CZ300324B6 (da)
DE (1) DE60033280T2 (da)
DK (1) DK1185525T3 (da)
ES (1) ES2280198T3 (da)
HK (1) HK1044943B (da)
HR (1) HRP20010630B1 (da)
HU (1) HUP0200080A3 (da)
ID (1) ID30484A (da)
IL (1) IL145051A0 (da)
MA (1) MA26776A1 (da)
NO (1) NO320809B1 (da)
NZ (1) NZ513671A (da)
PL (1) PL198815B1 (da)
PT (1) PT1185525E (da)
RS (1) RS50109B (da)
RU (1) RU2201928C1 (da)
TR (1) TR200102562T2 (da)
WO (1) WO2000052007A1 (da)
ZA (1) ZA200107157B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140724A (en) 2000-07-21 2010-01-15 Actelion Pharmaceuticals Ltd Novel arylethene-sulfonamides
US20020184047A1 (en) * 2001-04-03 2002-12-05 Plotnick Michael A. Universal ad queue
EP1454625A1 (en) * 2003-03-06 2004-09-08 Speedel Development AG Pyridylsulfonamidyl-pyrimidines for the treatment of diabetic nephropathies
EP1595880A1 (en) * 2004-05-13 2005-11-16 Speedel Pharma AG Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists
WO2007031501A2 (en) * 2005-09-12 2007-03-22 Speedel Pharma Ag Pyridylsulfonamidyl-pyrimidines for the prevention of blood vessel graft failure
SG174050A1 (en) * 2006-04-13 2011-09-29 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
EP1938812A1 (en) * 2006-12-22 2008-07-02 Speedel Pharma AG Pharmaceutical composition using aliskiren and avosentan
US20100093758A1 (en) * 2008-07-23 2010-04-15 Auspex Pharmaceuticals, Inc. Pyridine sulfonamide modulators of endothelin-a receptor
US20180022710A1 (en) 2015-01-29 2018-01-25 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
KR101936054B1 (ko) 2017-06-23 2019-01-11 한국과학기술연구원 항염증 활성을 가지는 6-페녹시피리미딘 유도체, 이의 제조방법 및 이를 활성성분으로 하는 약학 조성물
AU2022416870A1 (en) 2021-12-17 2024-06-27 Nxera Pharma Co., Ltd. Clazosentan disodium salt, its preparation and pharmaceutical compositions comprising the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2162630C (en) 1994-11-25 2007-05-01 Volker Breu Sulfonamides
CN1064965C (zh) * 1994-11-25 2001-04-25 弗·哈夫曼-拉罗切有限公司 新的磺酰胺类化合物及其作为药物的用途
US5837708A (en) 1994-11-25 1998-11-17 Hoffmann-La Roche Inc. Sulphonamides
TW313568B (da) * 1994-12-20 1997-08-21 Hoffmann La Roche
DK0897914T3 (da) 1997-08-19 2004-09-27 Hoffmann La Roche Fremgangsmåde til fremstilling af 2,5-disubstituerede pyridiner
TWI284642B (en) * 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides

Also Published As

Publication number Publication date
NO20014224D0 (no) 2001-08-31
NO20014224L (no) 2001-08-31
AR044720A1 (es) 2005-10-05
RS50109B (sr) 2009-03-25
TR200102562T2 (tr) 2002-02-21
KR20010102480A (ko) 2001-11-15
ES2280198T3 (es) 2007-09-16
CA2364906C (en) 2006-01-10
HK1044943A1 (da) 2002-11-08
US6417360B1 (en) 2002-07-09
HRP20010630A2 (en) 2002-08-31
EP1185525A1 (en) 2002-03-13
EP1185525B1 (en) 2007-02-07
CY1108002T1 (el) 2013-09-04
CN1342158A (zh) 2002-03-27
PT1185525E (pt) 2007-05-31
HUP0200080A3 (en) 2003-01-28
WO2000052007A1 (en) 2000-09-08
RU2001126348A (ru) 2004-03-20
NZ513671A (en) 2003-04-29
AU3161100A (en) 2000-09-21
HRP20010630B1 (en) 2010-08-31
CA2364906A1 (en) 2000-09-08
DE60033280T2 (de) 2007-11-22
ZA200107157B (en) 2002-11-29
PL198815B1 (pl) 2008-07-31
US6521631B2 (en) 2003-02-18
BR0008717A (pt) 2001-12-26
NO320809B1 (no) 2006-01-30
JP2002538156A (ja) 2002-11-12
CZ300324B6 (cs) 2009-04-22
MA26776A1 (fr) 2004-12-20
DE60033280D1 (de) 2007-03-22
JP3488203B2 (ja) 2004-01-19
ATE353325T1 (de) 2007-02-15
AU756738B2 (en) 2003-01-23
RU2201928C1 (ru) 2003-04-10
CZ20013108A3 (cs) 2002-02-13
HK1044943B (zh) 2013-03-22
KR100478798B1 (ko) 2005-03-24
IL145051A0 (en) 2002-06-30
US20020137933A1 (en) 2002-09-26
PL351794A1 (en) 2003-06-16
HUP0200080A2 (en) 2002-06-29
YU62801A (sh) 2004-07-15
ID30484A (id) 2001-12-13
CN1342158B (zh) 2012-06-06

Similar Documents

Publication Publication Date Title
NO20013454D0 (no) 4-(Heterocyklylsulfonamido)-5-metoksy-6-(2-metoksyfenoksy)-2- fenyl- eller -pyridylpyrimidiner som endotelinreseptor-antagonister
DK0901470T3 (da) Indolderivater egnede som endothelinreceptorantagonister
NO20015366D0 (no) Piperazinderivater som er anvendbare som CCR5-antagonister
NO975976L (no) Vitronektinreseptor-antagonister, fremstilling samt anvendelse derav
EP1254116A4 (en) ALPHA V INTEGRIN RECEPTOR ANTAGONISTS
EP1252162A4 (en) ALPHA V INTEGRIN RECEPTOR ANTAGONISTS
NO991079L (no) Azinyloksy- og fenoksy-diaryl-karboksylsyre-derivater, deres fremstilling og deres anvendelse som blandede ETA/ETB-endotelin-reseptor-antagonister
NO975975D0 (no) Vitronektinreseptor-antagonister, fremstilling samt anvendelse derav
AU2001290772A1 (en) Alpha v integrin receptor antagonists
DK1185525T3 (da) 4-heterocyclylsulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidinderivater, fremstilling deraf samt anvendelse deraf som endothelinreceptorantagonister
NO20016247L (no) Streptograminderivater, deres fremstilling samt preparater inneholdende derivatene
AU9259801A (en) Alpha v integrin receptor antagonists
NO20004144D0 (no) Heterocykliske forbindelser, deres fremstilling og anvendelse som takykinin reseptor antagonister
DE50008020D1 (de) Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten
NO992976L (no) Heterocykliske karboksylsyre-derivater, fremstilling og anvendelse derav som endothelinreseptor-antagonister
AUPQ570100A0 (en) Beta-alanine derivatives and their use as receptor antagonists
NO20014692L (no) 3-amidinobenzensulfonamidderivater, medisinske sammensetninger inneholdende slike samt intermediater vedfremstillingen derav
NO20015237D0 (no) Integrinreseptor-antagonister
AU1025601A (en) Tetrahydrobenzindolone derivatives, their preparation and their use as 5-ht7 receptor antagonists
EP1169042A4 (en) DIBENZO-AZEPINE DERIVATIVES AS ANTAGONISTS OF THE ALPHA V INTEGRIN RECEPTOR
ITBO990417A0 (it) Perno per uso odontoiatrico .
NO20004075D0 (no) Substituerte pyrimidin-2-yloksy-karboksylsyrederivater, fremstilling av disse og deres anvendelse som endotelin- antagonister
ZA9810425B (en) Novel heterocyclically substituted Ó-hydroxycarboxylic acid derivatives, their preparation and use as endothelin receptor antagonists.
AU9088401A (en) Alpha v integrin receptor antagonists
IL143451A0 (en) NEW- β-AMIDE AND β-SULFONAMIDE CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS